CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.

Henan Cancer Hospital

Status and phase: Unknown; Phase 2; Phase 1

Conditions: B-cell Acute Lymphocytic Leukemia

Treatments: Drug: Fludarabine; Biological: CD19 CAR-T; Drug: Cyclophosphamide

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT03263208

HenanCH152

Details and patient eligibility

About

The purpose of this study is to infusion CD19 CAR-T cells to the patients with relapsed and refractory CD19+ B cell leukemia, to assess the safety and feasibility of this strategy. The CAR enables the T cell to recognize and kill the leukemic cell through the recognition of CD19, a protein expressed of the surface of the leukemic cell in patients with CD19+ leukemia.

Full description

Upon meeting the eligibility requirements and enrolling on study, Subjects will be collected large numbers of peripheral blood mononuclear cells (PBMC) for the generation of the CD19 CAR-T cells. The T cells are isolated from the PBMC, transduced with a lentivirus to express the CD19 CAR as well as a truncated EGFR that has no signaling capacity (noted EGFRt) and expanded in vitro and then administered to subjects.

Subjects will have blood tests to assess safety and efficacy, and persistence of the CD19 CAR-T cells on week 4 after their last infusion. Following the 6 months of intensive follow-up, subjects will be evaluated every 10 weeks for 1 year with a physical examination, blood tests, bone marrow aspirate, MRD and persistence of CD19 CAR-T.

Some subjects will receive cetuximab for ablation of the genetically modified T cells. Criteria to receive cetuximab include acute toxicities that are life threatening.

Enrollment: 20 estimated patients

Sex: All

Ages: 2 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 1. 2 years to 70 years, expected survival > 3 months;
• 2. CD19 positive B-cell acute lymphoblastic leukemia;
• 3. ECOG < 2；
• 4. The tumor load in the bone marrow is less than 60%;
• 5. Cardiac function: 1-2 levels; Liver: TBIL≤3ULN，AST ≤2.5ULN，ALT ≤2.5ULN; kidney: Cr≤1.25ULN; Peripheral Blood: WBC ≥ 2.0×109/L, Hb ≥80 g/L, PLT ≥ 30×109/L）;
• 6. No leukemia cells in the central nervous system;
• 7. No serious allergic constitution;
• 8. No other serous diseases that conflicts with the clinical program;
• 9. No other cancer history;
• 10. No serious mental disorder;
• 11. female participants of reproductive potential must have a negative serum pregnancy test;
• 12. Informed consent is signed by a subject or his lineal relation.

Exclusion criteria

• 1. Pregnant or lactating women;
• 2. Uncontrolled active infection, HIV infection, syphilis serology reaction positive;
• 3. Active hepatitis B or hepatitis C infection;
• 4. Recent or current use of glucocorticoid or other immunosuppressor;
• 5. With severe cardiac, liver, renal insufficiency, diabetes and other diseases;
• 6. Participate in other clinical research in the past three months; previously treatment with any gene therapy products;

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

CD19 CAR-T

Experimental group

Description:

A conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.

Treatment:

Drug: Fludarabine

Biological: CD19 CAR-T

Drug: Cyclophosphamide